Anxiolytic efficacy of Sphaeranthus indicus Linn Ghana Vati in Generalized Anxiety Disorder: A randomized, placebo-controlled trial

Sumedh Joshi , Bhargav Vijay Bhide , Shivani Ghildiyal , Tanuja Manoj Nesari
{"title":"Anxiolytic efficacy of Sphaeranthus indicus Linn Ghana Vati in Generalized Anxiety Disorder: A randomized, placebo-controlled trial","authors":"Sumedh Joshi ,&nbsp;Bhargav Vijay Bhide ,&nbsp;Shivani Ghildiyal ,&nbsp;Tanuja Manoj Nesari","doi":"10.1016/j.bbii.2025.100110","DOIUrl":null,"url":null,"abstract":"<div><div>Generalized Anxiety Disorder (GAD) is a prevalent psychiatric condition marked by persistent worry that disrupts daily life. Conventional treatments, such as SSRIs and benzodiazepines, are often limited by side effects, including sedation and dependence. Sphaeranthus indicus Linn., a well-known Ayurvedic herb, has shown promising anxiolytic potential. This randomized, single-blind, placebo-controlled trial evaluated the efficacy and safety of Sphaeranthus indicus Ghana Vati (SIGV) in patients with GAD. Fifty patients diagnosed according to DSM-IV criteria were randomly assigned to receive either SIGV (500 mg, twice daily) or placebo for eight weeks. Anxiety reduction, the primary outcome, was measured using the Hamilton Anxiety Rating Scale (HAM-A), while secondary outcomes included psychological assessments with the NIMHANS Screening Tool and Manas Bhava Parikshana. The SIGV group exhibited significantly greater improvement in anxiety symptoms than the placebo group. Reductions in anxious mood (63.2 % vs. 41.7 %, p &lt; 0.05), tension (64.0 % vs. 40.4 %, p &lt; 0.01), and insomnia (72.9 % vs. 43.9 %, p &lt; 0.001) were notable. The most significant difference was observed in fear reduction (80.0 % vs. 44.7 %, p &lt; 0.001). Additionally, improvements in depressed mood (62.2 % vs. 41.5 %, p &lt; 0.05) and somatic complaints were significant. However, autonomic symptom improvement (17.8 % vs. 38.1 %) did not reach statistical significance (p = 0.08). These findings suggest that SIGV is a safe and effective intervention for GAD, producing substantial improvements in core anxiety symptoms and emotional well-being compared to placebo. The results highlight SIGV’s potential as a natural and well-tolerated treatment option. Further research is warranted to assess its long-term efficacy and explore its integration into standard psychiatric care.</div></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":"10 ","pages":"Article 100110"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Behavior and Immunity Integrative","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S294983412500008X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Generalized Anxiety Disorder (GAD) is a prevalent psychiatric condition marked by persistent worry that disrupts daily life. Conventional treatments, such as SSRIs and benzodiazepines, are often limited by side effects, including sedation and dependence. Sphaeranthus indicus Linn., a well-known Ayurvedic herb, has shown promising anxiolytic potential. This randomized, single-blind, placebo-controlled trial evaluated the efficacy and safety of Sphaeranthus indicus Ghana Vati (SIGV) in patients with GAD. Fifty patients diagnosed according to DSM-IV criteria were randomly assigned to receive either SIGV (500 mg, twice daily) or placebo for eight weeks. Anxiety reduction, the primary outcome, was measured using the Hamilton Anxiety Rating Scale (HAM-A), while secondary outcomes included psychological assessments with the NIMHANS Screening Tool and Manas Bhava Parikshana. The SIGV group exhibited significantly greater improvement in anxiety symptoms than the placebo group. Reductions in anxious mood (63.2 % vs. 41.7 %, p < 0.05), tension (64.0 % vs. 40.4 %, p < 0.01), and insomnia (72.9 % vs. 43.9 %, p < 0.001) were notable. The most significant difference was observed in fear reduction (80.0 % vs. 44.7 %, p < 0.001). Additionally, improvements in depressed mood (62.2 % vs. 41.5 %, p < 0.05) and somatic complaints were significant. However, autonomic symptom improvement (17.8 % vs. 38.1 %) did not reach statistical significance (p = 0.08). These findings suggest that SIGV is a safe and effective intervention for GAD, producing substantial improvements in core anxiety symptoms and emotional well-being compared to placebo. The results highlight SIGV’s potential as a natural and well-tolerated treatment option. Further research is warranted to assess its long-term efficacy and explore its integration into standard psychiatric care.
加纳白球对广泛性焦虑障碍的抗焦虑疗效:一项随机、安慰剂对照试验
广泛性焦虑障碍(GAD)是一种普遍的精神疾病,其特征是持续的担忧扰乱了日常生活。传统的治疗方法,如SSRIs和苯二氮卓类药物,往往受到副作用的限制,包括镇静和依赖性。凤仙花一种著名的阿育吠陀草药,已经显示出有希望的抗焦虑潜力。这项随机、单盲、安慰剂对照试验评估了Sphaeranthus indicus Ghana Vati (SIGV)对广泛性焦虑症患者的疗效和安全性。根据DSM-IV标准诊断的50例患者被随机分配接受SIGV(500 mg,每日两次)或安慰剂,为期8周。焦虑减少是主要结果,使用汉密尔顿焦虑评定量表(HAM-A)进行测量,而次要结果包括使用NIMHANS筛选工具和Manas Bhava Parikshana进行心理评估。SIGV组在焦虑症状上的改善明显大于安慰剂组。减少焦虑情绪(63.2 % 41.7 vs %,p & lt; 0.05),张力(64.0 % 40.4 vs % p & lt; 0.01),和失眠(72.9 % 43.9 vs % p & lt; 0.001)是显著的。最显著的差异是恐惧减少(80.0 % vs. 44.7 %,p <; 0.001)。此外,抑郁情绪的改善(62.2% % vs. 41.5% %,p <; 0.05)和躯体不适也有显著改善。然而,自主神经症状改善(17.8 % vs. 38.1 %)没有达到统计学意义(p = 0.08)。这些发现表明,与安慰剂相比,SIGV是一种安全有效的广泛性焦虑症干预措施,可显著改善核心焦虑症状和情绪健康。结果突出了SIGV作为一种天然且耐受性良好的治疗选择的潜力。需要进一步的研究来评估其长期疗效,并探索其与标准精神病学治疗的结合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信